









Markets
/
Stocks
/
nasdaq-qntm
/

Quantum BioPharma Ltd

QNTM

4.200USD

+0.280+7.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

16.03MMarket Cap

LossP/E TTM



Quantum BioPharma Ltd

4.200

+0.280+7.14%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Quantum BioPharma Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Quantum BioPharma Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 166 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.25.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Quantum BioPharma Ltd's Score

Industry at a Glance

Industry Ranking

166 / 392

Overall Ranking

317 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Quantum BioPharma Ltd Highlights

StrengthsRisks

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Overvalued

The company’s latest PE is -0.47, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.11M shares, increasing 13.26% quarter-over-quarter.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

40.250

Target Price

+926.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Quantum BioPharma Ltd is 6.69, ranking 229 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.69

Change



Financials

8.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Quantum BioPharma Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Quantum BioPharma Ltd is 6.08, ranking 333 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.47, which is -52.18% below the recent high of -0.23 and -528.64% above the recent low of -2.97.

Score

Industry at a Glance

Previous score

6.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 166/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Quantum BioPharma Ltd is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 40.25, with a high of 45.00 and a low of 35.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

40.250

Target Price

+926.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Quantum BioPharma Ltd

QNTM

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Quantum BioPharma Ltd is 5.62, ranking 307 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.55 and the support level at 2.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.54

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.196

Sell

RSI(14)

28.644

Sell

STOCH(KDJ)(9,3,3)

15.908

Buy

ATR(14)

0.519

High Vlolatility

CCI(14)

-77.331

Neutral

Williams %R

87.288

Oversold

TRIX(12,20)

-2.322

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.078

Buy

MA10

4.529

Sell

MA20

5.688

Sell

MA50

7.602

Sell

MA100

10.413

Sell

MA200

13.867

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Malone Wealth Ventures LLC

1.05M

+26.20%

Saeed (Zeeshan)

118.41K

+0.25%

Carroll (Donal)

90.41K

+9.30%

Lynch (Terrence)

51.42K

AdvisorShares Investments, LLC

37.24K

+0.67%

Kotra (Lakshmi)

29.57K

Durkacz (Anthony)

29.11K

-72.73%

Marex Group plc

13.44K

Saeed (Rehan)

6.79K

-24.09%

Xorax Family Trust

6.79K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Quantum BioPharma Ltd is 1.38, ranking 321 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.